Get the Stockscreener App
33.26
0.60%
-0.20
After Hours:
32.96
-0.30
-0.90%
Phibro Animal Health Corp stock is traded at $33.26, with a volume of 252.12K.
It is down -0.60% in the last 24 hours and down -38.37% over the past month.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
See More
Previous Close:
$33.46
Open:
$33.49
24h Volume:
252.12K
Relative Volume:
0.75
Market Cap:
$1.35B
Revenue:
$1.46B
Net Income/Loss:
$92.09M
P/E Ratio:
14.75
EPS:
2.2555
Net Cash Flow:
$47.29M
1W Performance:
-3.23%
1M Performance:
-38.37%
6M Performance:
-20.11%
1Y Performance:
+44.48%
1-Day Range:
$32.74
$34.00
1-Week Range:
$32.30
$35.94
52-Week Range:
$22.51
$60.08
Phibro Animal Health Corp Stock (PAHC) Company Profile
Name
Phibro Animal Health Corp
Sector
Phone
201-329-7300
Address
GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ
Compare PAHC vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAHC
Phibro Animal Health Corp
|
33.26 | 1.36B | 1.46B | 92.09M | 47.29M | 2.2555 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Phibro Animal Health Corp Stock (PAHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Jul-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-16-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-10-24 | Initiated | JP Morgan | Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Underperform |
| Dec-21-22 | Initiated | ROTH Capital | Buy |
| Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-07-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Aug-06-20 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Jan-28-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-29-19 | Reiterated | BofA/Merrill | Underperform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| May-23-19 | Initiated | Guggenheim | Neutral |
| May-09-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-23-17 | Resumed | BofA/Merrill | Underperform |
| Jun-02-17 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-15-16 | Initiated | Piper Jaffray | Overweight |
| Nov-11-16 | Downgrade | Macquarie | Neutral → Underperform |
| Nov-10-16 | Downgrade | Gabelli & Co | Buy → Hold |
| Apr-11-16 | Reiterated | Guggenheim | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Jan-15-16 | Downgrade | Barclays | Overweight → Underweight |
| Sep-30-15 | Initiated | Gabelli & Co | Buy |
| Apr-24-15 | Reiterated | Barclays | Overweight |
| Apr-21-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-06-14 | Initiated | Barclays | Overweight |
View All
Phibro Animal Health Corp Stock (PAHC) Latest News
Phibro's CEO transition puts this insider sale in context - AOL.com
Phibro's CEO transition puts this insider sale in context - The Motley Fool
Phibro Animal Health (PAHC) major holder adopts 10b5-1 sale plan - Stock Titan
PAHC Stock Price, Quote & Chart | PHIBRO ANIMAL HEALTH CORP-A (NASDAQ:PAHC) - ChartMill
Phibro leaders to address investors at Stifel 'Jaws & Paws' in New York - Stock Titan
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference - Yahoo Finance
PAHC Technical Analysis & Stock Price Forecast - Intellectia AI
Phibro Animal Health Corporation (PAHC) Price Target Cut to $44 by Citi Amid Sector Pressure - Insider Monkey
Phibro Animal Health (PAHC): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Phibro (PAHC) Q1 2026 Earnings: EPS $0.76 Beats EstimatesSocial Buy Zones - Newser
Barclays PLC holds 263,695 shares in Phibro (NASDAQ: PAHC) - Stock Titan
PAHC Maintained by Citigroup -- Price Target Lowered to $44 - GuruFocus
Phibro Animal Health Corp at Bank of America Global Healthcare Conference Transcript - GuruFocus
Phibro Animal Health Sales Grow 10 Percent to 383 Million Dollars - HarianBasis.co
Earnings call transcript: Phibro Animal Health Q3 2026 sees earnings beat, stock tumbles - Investing.com
Phibro Animal Health Corporation (PAHC) Announces Financial Results for Q3 - Insider Monkey
Phibro Animal Health Corp (FRA:PB8) Stock Price & 30 Year Financial Data - GuruFocus
Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term - Yahoo Finance
Q2 2026 Phibro Animal Health Corp Earnings Call Transcript - GuruFocus
Why Phibro Animal Health (PAHC) is a Top Growth Stock for the Long-Term - Yahoo Finance
Down 30.9% in 4 Weeks, Here's Why Phibro (PAHC) Looks Ripe for a Turnaround - Yahoo Finance
Deciphering Phibro (PAHC) International Revenue Trends - Yahoo Finance
Q3 2026 Phibro Animal Health Corp Earnings Call Transcript - GuruFocus
PAHCPhibro Animal Health Corp Stock Price and Quote - Finviz
Phibro Sustainable Solutions Platform helps protein producers target greenhouse gas emissions - The National Provisioner
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now? - Yahoo Finance
PAHC Stock Falls Despite Q3 Earnings & Revenue Beat, Margins Rise - Yahoo Finance
Phibro Animal Health CEO Jack Bendheim sells $1.02m in PAHC shares By Investing.com - Investing.com Australia
Phibro Animal Health CEO Jack Bendheim sells $1.02m in PAHC shares - Investing.com
CEO-linked BFI Co. (PAHC) sells 18,608 Phibro shares under plan - Stock Titan
Phibro executives take Bank of America health conference stage May 13 - Stock Titan
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference - ChartMill
Phibro Q3 FY2026 slides: 10% sales growth amid regulatory headwinds - Investing.com
Earnings call transcript: Phibro Animal Health beats Q3 2026 expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Phibro Animal Health beats Q3 2026 expectations - Investing.com
Phibro Animal Health Reports Strong Q3 2026 Results, Raises Full-Year Guidance with 14% Sales Growth - Minichart
Phibro Animal Health Corp reports results for the quarter ended March 31Earnings Summary - TradingView
MSN Money - MSN
Compared to Estimates, Phibro (PAHC) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Phibro Animal Health (PAHC) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Phibro: Fiscal Q3 Earnings Snapshot - KTVB
Phibro Animal Health (PAHC) posts 10% Q3 sales growth and raises 2026 guidance - Stock Titan
Phibro Animal Health’s (NASDAQ:PAHC) Q1 CY2026: Beats On Revenue - Yahoo Finance
Animal health demand pushes Phibro sales to $383.5M in Q3 - Stock Titan
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance - marketscreener.com
Phibro Animal Health (PAHC) lifts sales and profit in Q3 2026 - Stock Titan
Phibro Animal Health earnings on deck: Can MFA momentum hold? By Investing.com - Investing.com South Africa
Phibro Animal Health earnings on deck: Can MFA momentum hold? - Investing.com
Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership - 01net
Phibro Animal Health Corporation Launches Companywide Sustainable - The National Law Review
Phibro Animal Health Corp Stock (PAHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):